CA3133589A1 - A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing - Google Patents

A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing

Info

Publication number
CA3133589A1
CA3133589A1 CA3133589A CA3133589A CA3133589A1 CA 3133589 A1 CA3133589 A1 CA 3133589A1 CA 3133589 A CA3133589 A CA 3133589A CA 3133589 A CA3133589 A CA 3133589A CA 3133589 A1 CA3133589 A1 CA 3133589A1
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
diazaspiro
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3133589A
Other languages
English (en)
French (fr)
Inventor
Magdalena Alonso-Galicia
David Carpenter
Thomas PACK
Melissa Rhodes
Julie RURKA
Steve WRING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altavant Sciences GmbH
Original Assignee
Altavant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altavant Sciences GmbH filed Critical Altavant Sciences GmbH
Publication of CA3133589A1 publication Critical patent/CA3133589A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3133589A 2019-03-15 2020-03-13 A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing Pending CA3133589A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819162P 2019-03-15 2019-03-15
US62/819,162 2019-03-15
PCT/IB2020/000177 WO2020188352A1 (en) 2019-03-15 2020-03-13 A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing

Publications (1)

Publication Number Publication Date
CA3133589A1 true CA3133589A1 (en) 2020-09-24

Family

ID=71092560

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3133589A Pending CA3133589A1 (en) 2019-03-15 2020-03-13 A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing

Country Status (9)

Country Link
US (2) US11576915B2 (https=)
EP (1) EP3938043A1 (https=)
JP (1) JP2022525202A (https=)
KR (1) KR20210139293A (https=)
CN (1) CN113784717A (https=)
AU (1) AU2020244278A1 (https=)
CA (1) CA3133589A1 (https=)
MX (1) MX2021011224A (https=)
WO (1) WO2020188352A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022507533A (ja) * 2018-11-16 2022-01-18 アルタバント・サイエンシズ・ゲーエムベーハー 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
US11607413B2 (en) * 2019-01-30 2023-03-21 Altavant Sciences Gmbh Dosage regime and method for treating pulmonary arterial hypertension
US11576915B2 (en) 2019-03-15 2023-02-14 Altavant Sciences Gmbh Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
WO2023062595A1 (en) * 2021-10-14 2023-04-20 Altavant Sciences Gmbh Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101815534A (zh) * 2007-07-11 2010-08-25 莱西肯医药有限公司 用于治疗肺动脉高压以及相关疾病和病症的方法和组合物
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
US9399741B2 (en) 2013-10-09 2016-07-26 Uop Llc Methods and apparatuses for desulfurizing hydrocarbon streams
KR20210102887A (ko) * 2018-11-14 2021-08-20 알타반트 사이언시스 게엠베하 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
JP2022507533A (ja) * 2018-11-16 2022-01-18 アルタバント・サイエンシズ・ゲーエムベーハー 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
US20200188399A1 (en) 2018-12-17 2020-06-18 Altavant Sciences Gmbh Method for treating interstitial lung disease
WO2020128608A1 (en) * 2018-12-17 2020-06-25 Altavant Sciences Gmbh Compound for use in a method for treating sarcoidosis-associated pulmonary hypertension
US11607413B2 (en) 2019-01-30 2023-03-21 Altavant Sciences Gmbh Dosage regime and method for treating pulmonary arterial hypertension
US11576915B2 (en) 2019-03-15 2023-02-14 Altavant Sciences Gmbh Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing

Also Published As

Publication number Publication date
US11576915B2 (en) 2023-02-14
US20200289510A1 (en) 2020-09-17
AU2020244278A1 (en) 2021-09-30
JP2022525202A (ja) 2022-05-11
KR20210139293A (ko) 2021-11-22
EP3938043A1 (en) 2022-01-19
US20240024316A1 (en) 2024-01-25
WO2020188352A1 (en) 2020-09-24
CN113784717A (zh) 2021-12-10
MX2021011224A (es) 2021-12-10

Similar Documents

Publication Publication Date Title
US11911382B2 (en) Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
US20240024316A1 (en) Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
CA2807135C (en) Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
US9522129B2 (en) Pharmaceutical Combination
US20220096475A1 (en) Method for treating sarcoidosis-associated pulmonary hypertension
WO2007149283B1 (en) Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload
US20200121704A1 (en) Methods for treating hypertension and arterial stiffness
EP3917531A1 (en) A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl
US9642860B2 (en) Combinations of corroles and statins
KR20150020160A (ko) 과민성 방광의 치료를 위한 무스카린 수용체 길항제 및 베타―3 아드레날린 수용체 작용제의 조합물
WO2005084392A2 (en) 4-methylpyrazole formulations for inhibiting ethanol intolerance
HK40065546A (en) A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
HK40058221A (en) A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
RU2774970C2 (ru) Применение карбаматных соединений для профилактики, облегчения или лечения биполярного расстройства
DE102004040630A1 (de) Kombinationstherapie mit Procain
WO2005117853A1 (ja) 高脂血症治療剤及び糖尿病治療剤
HK40015213A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250902

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251103